Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of parkinson's disease and L-DOPA-induced dyskinesia

Journal of Molecular Neuroscience

Volumn 46, Issue 1, 2012, Pages 145-152

  Alachkar, Amal ^a   Brotchie, Jonathan M ^b   Jones, Owen T ^c  

^a UNIVERSITY OF ALEPPO   (Syrian Arab Republic)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

6 OHDA; Alpha2A adrenoceptors; Alpha2C adrenoceptors; Gene expression; L DOPA induced dyskinesia; Parkinson's disease

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; BENSERAZIDE; LEVODOPA; MESSENGER RNA; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DYSKINESIA; GENE EXPRESSION; LOCUS CERULEUS; MALE; NONHUMAN; PARKINSON DISEASE; RAT; SHAM PROCEDURE; ADRENERGIC TRANSMISSION; ANIMAL CELL; ANIMAL TISSUE; BASAL GANGLION; CORPUS STRIATUM; GENE; IN SITU HYBRIDIZATION; MOTOR PERFORMANCE; NUCLEOTIDE SEQUENCE; SUPERIOR COLLICULUS;

RATTUS;

ADRENERGIC AGENTS; ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; LEVODOPA; LOCUS COERULEUS; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2; RNA, MESSENGER;

EID: 84858864250     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-011-9539-x     Document Type: Article

References (58)

1. Alachkar A, Brotchie JM, Jones OT (2010) Binding of dopamine and 3-methoxytyramine as l-DOPA metabolites to human alpha(2)-adrenergic and dopaminergic receptors. Neurosci Res 67(3):245-249
2. Alachkar A, Brotchie J, Jones OT (2006) alpha2-Adrenoceptor-mediated modulation of the release of GABA and noradrenaline in the rat substantia nigra pars reticulata. Neurosci Lett 395 (2):138-142 (Pubitemid 43188880)
3. Alam M, Danysz W, Schmidt WJ, Dekundy A (2009) Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats. Toxicol Appl Pharmacol 240(2):198-207
4. Aoki C, Go CG, Venkatesan C, Kurose H (1994) Perikaryal and synaptic localization of alpha 2A-adrenergic receptor-like immunoreactivity. Brain Res 650(2):181-204 (Pubitemid 24207063)
5. Bertrand E, Lechowicz W, Szpak GM, Dymecki J (1997) Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. Folia Neuropathol 35(2):80-86 (Pubitemid 127535387)
6. Bosboom JL, Wolters E (2004) Psychotic symptoms in Parkinson's disease: pathophysiology and management. Expert Opin Drug Saf 3(3):209-220 (Pubitemid 38765203)
7. Boyajian CL, Loughlin SE, Leslie FM (1987) Anatomical evidence for alpha-2 adrenoceptor heterogeneity: differential autoradiographic distributions of [3H]rauwolscine and [3H]idazoxan in rat brain. J Pharmacol Exp Ther 241(3):1079-1091
8. Brotchie JM (2005) Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 20(8):919-931
9. Buck K, Ferger B (2009) Comparison of intrastriatal administration of noradrenaline and L-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. Neuroscience 159(1):16-20
10. Colosimo C, Craus A (2003) Noradrenergic drugs for levodopa-induced dyskinesia. Clin Neuropharmacol 26(6):299-305 (Pubitemid 37505436)
11. Crossman AR (1990) A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 5(2):100-108
12. Dekundy A, Lundblad M, Danysz W, Cenci MA (2007) Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179(1):76-89 (Pubitemid 46441485)
13. Devoto P, Flore G, Vacca G, Pira L, Arca A, Casu MA, Pani L, Gessa GL (2003) Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic. Psychopharmacol Berl 167(1):79-84 (Pubitemid 36535295)
14. Devoto P, Flore G, Saba P, Fa M, Gessa GL (2005) Co-release of noradrenaline and dopamine in the cerebral cortex elicited by single train and repeated train stimulation of the locus coeruleus. BMC Neurosci 6:31
15. Devoto P, Flore G, Saba P, Castelli MP, Piras AP, Luesu W, Viaggi MC, Ennas MG, Gessa GL (2008) 6-Hydroxydopamine lesion in the ventral tegmental area fails to reduce extracellular dopamine in the cerebral cortex. J Neurosci Res 86(7):1647-1658 (Pubitemid 351642458)
16. Dolphin A, Jenner P, Marsden CD (1976) Noradrenaline synthesis from L-DOPA in rodents and its relationship to motor activity. Pharmacol Biochem Behav 5(4):431-439 (Pubitemid 8011025)
17. Filion M, Tremblay L (1991) Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 547(1):142-151
18. Flordellis CS, Castellano M, Franco R, Zannis VI, Gavras H (1990) Expression of multiple alpha 2-adrenergic receptor messenger RNA species in rat tissues. Hypertension 15(6 Pt 2):881-887 (Pubitemid 20189474)
19. Fornai F, di Poggio AB, Pellegrini A, Ruggieri S, Paparelli A (2007) Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Curr Med Chem 14(22):2330-2334 (Pubitemid 47618041)
20. Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM (2001) Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 16(4):642-650 (Pubitemid 36040843)
21. Galvan A, Wichmann T (2008) Pathophysiology of parkinsonism. Clin Neurophysiol 119(7):1459-1474
22. Gesi M, Soldani P, Giorgi FS, Santinami A, Bonaccorsi I, Fornai F (2000) The role of the locus coeruleus in the development of Parkinson's disease. Neurosci Biobehav Rev 24(6):655-668 (Pubitemid 30625131)
23. Grimbergen YA, Langston JW, Roos RA, Bloem BR (2009) Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev Neurother 9(2):279-290
24. Grondin R, Hadj TA, Doan VD, Ladure P, Bedard PJ (2000) Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn Schmiedebergs Arch Pharmacol 361(2):181-186 (Pubitemid 30062450)
25. Guiard BP, El Mansari M, Blier P (2008a) Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus. Mol Pharmacol 74(5):1463-1475
26. Guiard BP, El Mansari M, Merali Z, Blier P (2008b) Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol 11(5):625-639 (Pubitemid 351931823)
27. Haapalinna A, Leino T, Heinonen E (2003) The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats. Naunyn Schmiedebergs Arch Pharmacol 368(5):342-351 (Pubitemid 37491493)
28. Henry B, Crossman AR, Brotchie JM (1998) Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia. Adv Neurol 78:53-61
29. Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM(1999) The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 14(5):744-753 (Pubitemid 29509616)
30. Hill MP, Brotchie JM (1999) The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat. Br J Pharmacol 128(7):1577-1585
31. Holmberg M, Scheinin M, Kurose H, Miettinen R (1999) Adrenergic alpha2C-receptors reside in rat striatal GABAergic projection neurons: comparison of radioligand binding and immunohistochemistry. Neuroscience 93(4):1323-1333 (Pubitemid 29397560)
32. Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45:19-34
33. Hudson JL, van Horne CG, Stromberg I, Brock S, Clayton J, Masserano J, Hoffer BJ, Gerhardt GA (1993) Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 626(1-2):167-174 (Pubitemid 23306825)
34. Jones BE, Halaris AE, McIlhany M, Moore RY (1977) Ascending projections of the locus coeruleus in the rat. I. Axonal transport in central noradrenaline neurons. Brain Res 127(1):1-21 (Pubitemid 8085584)
35. Lanier SM, Downing S, Duzic E, Homcy CJ (1991) Isolation of rat genomic clones encoding subtypes of the alpha 2-adrenergic receptor. Identification of a unique receptor subtype. J Biol Chem 266(16):10470-10478 (Pubitemid 21906826)
36. Lee A, Rosin DL, Van Bockstaele EJ (1998) alpha2A-adrenergic receptors in the rat nucleus locus coeruleus: subcellular localization in catecholaminergic dendrites, astrocytes, and presynaptic axon terminals. Brain Res 795(1-2):157-169 (Pubitemid 28337827)
37. Mitchell IJ, Boyce S, Sambrook MA, Crossman AR (1992) A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain 115(Pt 3):809-824
38. Nagatsu T, Sawada M (2007) Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl (72): 113-20
39. Nicholas AP, Pieribone V, Hokfelt T (1993) Distributions of mRNAs for alpha-2 adrenergic receptor subtypes in rat brain: an in situ hybridization study. J Comp Neurol 328(4):575-594 (Pubitemid 23046804)
40. Nishi K, Kondo T, Narabayashi H (1991) Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by Ldopa. Neurosci Lett 123(2):244-247
41. Norenberg W, Schoffel E, Szabo B, Starke K (1997) Subtype determination of soma-dendritic alpha2-autoreceptors in slices of rat locus coeruleus. Naunyn Schmiedebergs Arch Pharmacol 356(2):159-165 (Pubitemid 27341969)
42. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic, Sydney
43. Persson T, Waldeck B (1970) Further studies on the possible interaction between dopamine and noradrenaline containing neurons in the brain. Eur J Pharmacol 11(3):315-320
44. Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128(Pt 6):1314-1322 (Pubitemid 40826185)
45. Ribas C, Miralles A, Busquets X, Garcia-Sevilla JA (2001) Brain alpha(2)-adrenoceptors in monoamine-depleted rats: increased receptor density, G coupling proteins, receptor turnover and receptor mRNA. Br J Pharmacol 132(7):1467-1476 (Pubitemid 32281035)
46. Rommelfanger KS, Weinshenker D (2007) Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem Pharmacol 74(2):177-190 (Pubitemid 46890808)
47. Rommelfanger KS, Edwards GL, Freeman KG, Liles LC, Miller GW, Weinshenker D (2007) Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci USA 104(34):13804-13809 (Pubitemid 350003401)
48. Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM (2003) Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 18(8):872-883 (Pubitemid 37021161)
49. Scheinin M, Lomasney JW, Hayden-Hixson DM, Schambra UB, Caron MG, Lefkowitz RJ, Fremeau RT Jr (1994) Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain. Brain Res Mol Brain Res 21(1-2):133-149
50. Silverdale MA, McGuire S, McInnes A, Crossman AR, Brotchie JM (2001) Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp Neurol 169(2):400-406 (Pubitemid 32524434)
51. Srinivasan J, Schmidt WJ (2004a) The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action? Naunyn Schmiedebergs Arch Pharmacol 369(6):629-638 (Pubitemid 38823995)
52. Srinivasan J, Schmidt WJ (2004b) Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. Behav Brain Res 151(1-2):191-199 (Pubitemid 38501442)
53. Unnerstall JR, Kopajtic TA, Kuhar MJ (1984) Distribution of alpha 2 agonist binding sites in the rat and human central nervous system: analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents. Brain Res 319(1):69-101 (Pubitemid 14126014)
54. Uhlen S, Lindblom J, Johnson A, Wikberg JE (1997) Autoradiographic studies of central alpha 2A- and alpha 2C-adrenoceptors in the rat using [3H]MK912 and subtype-selective drugs. Brain Res 770(1-2):261-266 (Pubitemid 27468076)
55. Wang T, Zhang QJ, Liu J, Wu ZH, Wang S (2009) Firing activity of locus coeruleus noradrenergic neurons increases in a rodent model of Parkinsonism. Neurosci Bull 25(1):15-20
56. Yavich L, Sirvio J, Haapalinna A, Ylinen A, Mannisto PT (2003) Atipamezole, an alpha2-adrenoceptor antagonist, augments the effects of L-DOPA on evoked dopamine release in rat striatum. Eur J Pharmacol 462(1-3):83-89 (Pubitemid 36183738)
57. Zeng DW, Lynch KR (1991) Distribution of alpha 2-adrenergic receptor mRNAs in the rat CNS. Brain Res Mol Brain Res 10(3):219-225
58. Zhang W, Ordway GA (2003) The alpha (2C)-adrenoceptor modulates GABA release in mouse striatum. Brain Res Mol Brain Res 112 (1-2):24-32 (Pubitemid 36369243)